Alpha 2.0
Login Register
» Journals » J Thorac Oncol

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer

The Journal of Thoracic Oncology is the official publication of the International Association for the Study of Lung Cancer. It is a leading journal in the field of thoracic oncology, focusing on the latest research and advancements in the prevention, diagnosis, and treatment of lung cancer and other thoracic malignancies. With a multidisciplinary approach, the journal provides a platform for scientists, clinicians, and researchers to share their findings and contribute to the improvement of patient care and outcomes in this challenging field.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Details
Abbr. J Thorac Oncol
Publisher Elsevier
Start 2006
End Continuing
Frequency Nine no. a year
p-ISSN 1556-0864
e-ISSN 1556-1380
Country United States
Language English
Specialties Oncology
Pulmonary Medicine
Metrics
h-index / Ranks: 962 178
SJR / Ranks: 114 7879
CiteScore / Ranks: 137 31.90
JIF / Ranks: 149 20.4
Recent Articles
1.
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Hakozaki T, Tanaka K, Shiraishi Y, Sekino Y, Mitome N, Okuma Y, et al.
J Thorac Oncol . 2025 Mar; PMID: 40058642
Background: Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker, but its role...
2.
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells
Chen P, Wang H, Tang Z, Shi J, Cheng L, Zhao C, et al.
J Thorac Oncol . 2025 Mar; PMID: 40056978
Accumulation of regulatory T (Treg) cells, an immunosuppressive population, limits the efficacy of immunotherapy in non-small cell lung cancer (NSCLC). C-C Motif Chemokine Receptor 8 (CCR8) is selectively expressed in...
3.
Reply to: "AI Technologies for Patients With Immune-Related Adverse Events"
OReilly D, OLeary C, Naidoo J
J Thorac Oncol . 2025 Mar; 20(3):e48-e49. PMID: 40049772
No abstract available.
4.
Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing
Liu F, Li H
J Thorac Oncol . 2025 Mar; 20(3):e47-e48. PMID: 40049771
No abstract available.
5.
A Response to the Letter to the Editor: "Reply to Lei Wu et al."
Kim E, Bak M
J Thorac Oncol . 2025 Mar; 20(3):e46-e47. PMID: 40049770
No abstract available.
6.
Accurate Risk Factors of Cardiotoxicity in Patients With NSCLC Treated With Osimertinib
Wu L, Liu N, Sun M
J Thorac Oncol . 2025 Mar; 20(3):e44-e45. PMID: 40049769
No abstract available.
7.
A Response to the Letter to the Editor "Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?"
Marinelli D, Gallina F
J Thorac Oncol . 2025 Mar; 20(3):e43-e44. PMID: 40049768
No abstract available.
8.
Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Wu P, Li D, Zhang C, Sun N, He J
J Thorac Oncol . 2025 Mar; 20(3):e41-e42. PMID: 40049767
No abstract available.
9.
Reducing pERKs to Break "RAS"istance to Sotorasib
Gray S, OConnor D, Mutti L, Meirson T
J Thorac Oncol . 2025 Mar; 20(3):259-261. PMID: 40049766
No abstract available.
10.
Navigating the Complexity of Cerebral Prophylaxis: A Path Worth Taking?
Ramella S, Fiore M, DAngelillo R
J Thorac Oncol . 2025 Mar; 20(3):256-258. PMID: 40049765
No abstract available.